Peripartum cardiomyopathy: challenges in diagnosis and management

References

• Johnson NB, Hayes LD, Brown K, et al. Centers for Disease Control and Prevention (CDC). CDC national health report: leading causes of morbidity and mortality and associated behavioral risk and protective factors--United States, 2005–2013. MMWR Suppl. 2014 Oct 31;63(4):3–27.
   PubMedGoogle Scholar
• Arany Z, Elkayam U Peripartum cardiomyopathy. Circulation. 2016 Apr 5;133(14):1397–1409. doi:10.1161/CIRCULATIONAHA.115.020491.
   PubMed Web of Science ®Google Scholar
• Fett JD. Earlier detection can help avoid many serious complications of peripartum cardiomyopathy. Future Cardiol. 2013 Nov;9(6):809–816.
   PubMedGoogle Scholar
• Fett JD Peripartum cardiomyopathy: a puzzle closer to solution. World J Cardiol. 2014;6(3):81–114. Epub Mar 26.
   PubMedGoogle Scholar
• Bello N, Rendon ISH, Arany Z The relationship between preeclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis. J Am Coll Cardiol. 2013;62:1715–1723. Epub 2013 Sep 4.
   PubMed Web of Science ®Google Scholar
• McNamara DM, Elkayam U, Alharethi R, et al. Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC study (investigations of pregnancy-associated cardiomyopathy). J Am Coll Cardiol. 2015;66(8):905–914.
   PubMed Web of Science ®Google Scholar
• Safirstein JG, Ro AS, Grandhi S, et al. Predictors of left ventricular recovery in a cohort of peripartum cardiomyopathy patients recruited via the internet. Int J Cardiol. 2012 Jan 12;154(1):27–31. Epub 2010 Sep 20.
   PubMed Web of Science ®Google Scholar
• Ware JS, Li J, Mazaika E, et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. NEJM. 2016 Jan 21;374(3):233–241. doi:10.1056/NEJMoa1505517. Epub 2016 Jan 6.
   PubMed Web of Science ®Google Scholar
• Sheppard R, Hsich E, Damp J, et al. GNB3 C825T polymorphism and myocardial recovery in peripartum cardiomyopathy: results of the multicenter investigations of pregnancy-associated cardiomyopathy study. Circ Heart Fail. 2016 Mar;9(3):e002683.
   PubMed Web of Science ®Google Scholar
• Fett JD. Validation of a self-test for early diagnosis of heart failure in peripartum cardiomyopathy. Crit Pathw Cardiol. 2011 Mar;10:44–45.
   PubMedGoogle Scholar
• Damp J, Givertz MM, Semigran M, et al. Relaxin-2 and soluble Flt1 levels in peripartum cardiomyopathy: results of the multicenter IPAC study. JACCHF. 2016 May;4(5):380–388.
   Google Scholar
• Umazume T, Yamada T, Yamada S, et al. Peripartum cardiomyopathy in a woman with preeclampsia with twin pregnancy. BMJ Case Rep. 2014 Nov 20;2014:bcr2014208186. pii: bcr2014208186. doi:10.1136/bcr-2014-208186.
   PubMedGoogle Scholar
• Patten IS, Rana S, Shahul S, et al. Bauersachs cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012;485:333–338. PMID: 22596155. doi:10.1038/nature11040.
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381(9860):29–39.
   PubMed Web of Science ®Google Scholar
• Jeyabalan A, Shroff SG, Novak J, et al. The vascular actions of relaxin. Adv Exp Med Biol. 2007;612:65–87.
   PubMed Web of Science ®Google Scholar
• Wilson SS, Ayaz S, Levy PD. Relaxin: a novel agent for the treatment of acute heart failure. Pharmacotherapy. 2015;35(3):315–327.
   PubMed Web of Science ®Google Scholar
• Unemori EN, Lewis M, Constant J, et al. Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites. Wound Repair Regener. 2000;8(5):361–370.
   PubMed Web of Science ®Google Scholar
• Ansari AA, Fett JD, Carraway RE, et al. Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. Clin Rev Allergy Immunol. 2002 Dec;23:301–324.
   PubMed Web of Science ®Google Scholar
• Warraich RS, Sliwa K, Damasceno A, et al. Impact of pregnancy-related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy. Am Heart J. 2005;150:263–269.
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Baba A, Nagatomo Y Autoimmune mechanisms underlying dilated cardiomyopathy. Circ J. 2009;73:602–607. PMID: 19246813.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang Y, Chen M The correlation between peripartum cardiomyopathy and autoantibodies against cardiovascular receptors. PLoS One. 2014;9:e86770. PMID: 24466231. doi:10.1371/journal.pone.0086770.
   PubMed Web of Science ®Google Scholar
• Jahns R, Boivin V, Hein L, et al. Direct evidence for a β1-adrenergic receptor–directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest. 2004;113:1419–1429.
   PubMed Web of Science ®Google Scholar
• Freedmann NJ, Lefkowitz RJ. Anti–β1-adrenergic receptor antibodies and heart failure: causation, not just correlation. J Clin Invest. 2004;113:1379–1382.
   PubMed Web of Science ®Google Scholar
• Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007;128:589–600.
   PubMed Web of Science ®Google Scholar
• Sliwa K, Blauwet L, Tibazarwa K, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation. 2010;121:1465–1473.
   PubMed Web of Science ®Google Scholar
• Haghikia A, Podewski E, Libhaber E, et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol. 2013;108:366. PMID: 23812247. doi:10.1007/s00395-013-0366-9.
   PubMed Web of Science ®Google Scholar
• Kamiya CA, Kitakaze M, Ishibashi-Ueda H, et al. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. Results from the Japanese Nationwide survey of peripartum cardiomyopathy. Circ J. 2011;75(8):1975–1981. Epub 2011 May 27.
   Google Scholar
• Desplantie O, Tremblay-Gravel M, Avram R, et al. BRO-HF Initiative Investigators. The medical treatment of new-onset peripartum cardiomyopathy: a systematic review of prospective studies. Can J Cardiol. 2015 Dec;31(12):1421–1426. Epub 2015 May 2.
   Google Scholar
• American Heart Association. Heart Failure. In: Fuster V, editor. The AHA guidelines and scientific statements handbook. Oxford: Wiley-Blackwell; 2009.
   Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2013;62:e147–e239.
   PubMed Web of Science ®Google Scholar
• Duncker D, Haghikia A, König T, et al. Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function—value of the wearable cardioverter/defibrillator. Eur J Heart Fail. 2014;16:1331–1336.
   PubMed Web of Science ®Google Scholar
• Fett JD, Fristoe KL, Welsh SN Risk of heart failure relapse in subsequent pregnancy among peripartum cardiomyopathy mothers. Int J Gynecol Obstet. 2010;109:34–36.
   PubMed Web of Science ®Google Scholar
• Baughman KL. Peripartum cardiomyopathy. Curr Treat Options Cardiovasc Med. 2001 Dec;3(6):469–480.
   PubMedGoogle Scholar
• Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J. 2006;152:509–513.
   PubMed Web of Science ®Google Scholar
• Fett JD, Christie LG, Carraway RD, et al. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc. 2005 Dec;80:1602–1606.
   PubMed Web of Science ®Google Scholar
• Fett JD. Is it safe to discontinue treatment after full recovery from peripartum cardiomyopathy? JACC. 2016;67(13):1297–1287.
   Google Scholar